⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Home/Drugs/GB0139

GB0139

gb0139

Phase 2b

Sponsor: Galecto

Indication: IPF

Mechanism of Action

Galectin-3 inhibitor

Target: Galectin-3

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT03832946

A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Phase:PHASE2Org:Galecto Biotech AB

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

No recent publications found for gb0139.

Validated Models

This drug has been validated in the following preclinical models: